Dixon Hughes Goodman Wealth Advisors’s VYNE Therapeutics VYNE Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1K	Buy	+1	New	+$594	﹤0.01%	852

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's VYNE Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors opened a new position in VYNE Therapeutics (VYNE) in Q1 2022: 1 share worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #852 among its holdings.

41 funds tracked by Wall St. Rank hold VYNE as of Q1 2022.

Dixon Hughes Goodman Wealth Advisors held 1 share of VYNE Therapeutics worth $1K as of Q1 2022.
VYNE Therapeutics was a new Dixon Hughes Goodman Wealth Advisors position in Q1 2022.
VYNE Therapeutics made up ﹤0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #852 holding.
41 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.